1187056-39-8

Basic information

• Product Name: ethyl 2-cyano-2-(2,6-difluorobenzamido)acetate
• Synonyms: ethyl 2-cyano-2-(2,6-difluorobenzamido)acetate
• CAS NO: 1187056-39-8
• Molecular Formula: C12H10F2N2O3
• Molecular Weight: 268.22
• Mol File: 1187056-39-8.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: ethyl 2-cyano-2-(2,6-difluorobenzamido)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-cyano-2-(2,6-difluorobenzamido)acetate(1187056-39-8)
• EPA Substance Registry System: ethyl 2-cyano-2-(2,6-difluorobenzamido)acetate(1187056-39-8)

Safety Data

• Hazardous Substances Data: 1187056-39-8(Hazardous Substances Data)

Upstream product

• 18063-02-0 2,6-difluorobenzoylchloride 
• 32683-02-6 ethyl-2-aminocyano acetate 
• 105-56-6 ethyl 2-cyanoacetate 
• 3849-21-6 ethyl cyanoglyoxylate-2-oxime 

Downstream Products

• 1187056-41-2 ethyl 5-amino-2-(2,6-difluorophenyl)thiazole-4-carboxylate 
• 1187056-40-1 5-amino-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxylic acid 
• 1270034-25-7 5-[(tert-butoxycarbonyl)amino]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxylic acid 

Relevant articles and documents

2-substituted tricyclic oxazolo[5,4-d]pyrimidine library: Design, synthesis, and cytotoxicity activity

We report the design, synthetic route, and cytotoxicity of a library of 49 newly synthesized tricyclic oxazolo[5,4-d]pyrimidines. The condensed pyrimidinones were constructed from ethyl 5-aminooxazole-4-carboxylate building blocks. A tricyclic ring system was built using the naturally occurring mackinazolinone alkaloid with a focus on the molecular diversity at position C-2 of the oxazole ring. Synthesized compounds were evaluated against a panel of human cancer cell lines including MCF-7 (breast), HeLa (cervical), and A549 (lung) in vitro. The results revealed that substitution of halogen-related aromatic fragments at position C-2 of the oxazole ring may serve as promising anticancer drug candidates.

Tetrahydrooxazolopyridino-oxaazaone derivative and application of tetrahydrooxazolopyridino-oxaazaone derivative

The invention relates to a tetrahydrooxazolopyridino-oxaazaone derivative and application thereof. Specifically, the derivative tetrahydrooxazolo[5',4' : 4,5]pyridino[1, 2-a]oxaaza-11(5H)-one derivatives E1-E48. In anti-tumor activity screening, the positive control of DOX is used; the inhibition effect of the 48 tetrahydrooxazolo[5',4':4,5]pyridino[1, 2-a]oxaaza-11(5H)-one derivatives E1-E48 on Hela human cervical cancer cells, MCF-7 breast cancer cells and A549 lung cancer cells is observed, and the results show that compared with the positive control, the compounds E5, E8, E9, E20, E26, E28, E32, E34, E38, E41, E42, E44, E45, E46, E47 and E48 have the inhibition activity on the Hela cervical cancer cells, the compounds E26, E38, E42, E45, E46 and E47 have inhibitory activity on MCF-7 breast cancer cells; and the compounds E8, E9, E26 and E47 have inhibitory activity on A549 lung cancer cells.

Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma

Pim kinases have been targets of interest for a number of therapeutic areas. Evidence of durable single-agent efficacy in human clinical trials validated Pim kinase inhibition as a promising therapeutic approach for multiple myeloma patients. Here, we report the compound optimization leading to GDC-0339 (16), a potent, orally bioavailable, and well tolerated pan-Pim kinase inhibitor that proved efficacious in RPMI8226 and MM.1S human multiple myeloma xenograft mouse models and has been evaluated as an early development candidate.